Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.39 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.34 |
| ▸ | KDM6B | O15054 | 1/20 | 0.34 |
| ▸ | KDM5C | P41229 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.33 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.33 |
| ▸ | GABRP | O00591 | 2/20 | 0.32 |
| ▸ | GABRD | O14764 | 2/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3884537 | 0.92 | HDAC6 (0.44) | HDAC6HDAC1HDAC2NFKB1NFKB2 | |
| SCHEMBL5555258 | 0.83 | HDAC6 (0.57) | HDAC6HDAC1HDAC2LMNANFKB1 | |
| SCHEMBL8806268 | 0.80 | HDAC6 (0.41) | HDAC6HDAC1HDAC2NFKB1NFKB2 | |
| SCHEMBL27765894 | 0.80 | HDAC6 (0.46) | HDAC6HDAC1HDAC2LMNANFKB1 | |
| SCHEMBL4676227 | 0.80 | HDAC6 (0.46) | HDAC6HDAC1HDAC2LMNAGABRP | |
| SCHEMBL28595621 | 0.79 | PHF8 (0.45) | HDAC6HDAC1HDAC2PHF8KDM2A | |
| SCHEMBL5943153 | 0.77 | HDAC6 (0.51) | HDAC6HDAC1HDAC2LMNANFKB1 | |
| SCHEMBL8896065 | 0.77 | HDAC6 (0.51) | HDAC6HDAC1HDAC2LMNANFKB1 | |
| SCHEMBL1706932 | 0.77 | HDAC6 (0.38) | HDAC6HDAC1HDAC2NFKB1NFKB2 | |
| SCHEMBL5580137 | 0.77 | AKT1 (0.39) | HDAC6HDAC1HDAC2NFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1183049-B1 | MODIFICATION OF BIOLOGICAL ELEMENTS | HYBRID SYSTEMS LTD (GB) | 2009-01-14 | — | — | EP | disclosed |
| US-20080063701-A1 | Vector | IV VEC LIMITED (GB) | 2008-03-13 | — | — | US | disclosed |
| US-7279318-B1 | Modification of biological elements | HYBRID SYSTEMS LIMITED (GB) | 2007-10-09 | — | — | US | disclosed |
| EP-1814594-A2 | VECTOR COMPRISING POLYMER MODIFIED SIRNA LIPOSOMES | IC Vec Limited (GB) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006016097-A2 | VECTOR COMPRISING POLYMER MODIFIED SIRNA LIPOSOMES | IC VEC LIMITED (GB) | 2006-02-16 | — | — | WO | disclosed |
| EP-0941123-B1 | NUCLEIC ACID COMPLEXED WITH CATIONIC POLYMER USEFUL FOR GENE THERAPY | HYBRID SYSTEMS LTD (GB) | 2002-06-12 | — | — | EP | disclosed |
| EP-1183049-A2 | MODIFICATION OF BIOLOGICAL ELEMENTS | Hybrid Systems Limited (GB) | 2002-03-06 | — | — | EP | disclosed |
| US-6312727-B1 | SYNTHETIC POLYMER CARRIER VEHICLE FOR DELIVERY OF NUCLEIC ACID TO TARGET CELLS IN BIOLOGICAL SYSTEMS | HYBRID SYSTEMS LIMITED (GB) | 2001-11-06 | — | — | US | disclosed |
| WO-2000074722-A2 | MODIFICATION OF BIOLOGICAL ELEMENTS | HYBRID SYSTEMS LIMITED (GB) | 2000-12-14 | — | — | WO | disclosed |
| EP-0941123-A2 | DELIVERY OF NUCLEIC ACID MATERIAL TO TARGET CELLS IN BIOLOGICAL SYSTEMS | SCHACHT, Etienne Honoré (BE) | 1999-09-15 | — | — | EP | disclosed |
| WO-1998019710-A2 | DELIVERY OF NUCLEIC ACID MATERIAL TO TARGET CELLS IN BIOLOGICAL SYSTEMS | SCHACHT ETIENNE HONORE (BE) | 1998-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080063701-A1 | Vector | LPCAT1, HDLBP, AGO2 | HDAC6 1102/4885HDAC1 598/4885HDAC2 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.